Clinical bottom line
Systemic treatments for pediatric atopic dermatitis (AD) are increasingly important for moderate-to-severe cases unresponsive to topical therapies. Current evidence supports the cautious use of select biologics and immunomodulators, balancing efficacy with safety concerns unique to children. Dupilumab, a monoclonal antibody targeting IL-4/IL-13 pathways, has emerged as a leading option with favorable efficacy and safety profiles in children aged 6 months and older. Other systemic agents, including cyclosporine and methotrexate, remain options but require careful monitoring due to potential adverse effects. Overall, treatment decisions should be individualized, considering disease severity, comorbidities, and patient/family preferences, with ongoing evaluation of long-term safety data (Zemlok et al., 2024; Lugović-Mihić et al., 2024).
What the evidence shows
Pediatric AD presents unique therapeutic challenges due to developmental considerations and limited approved systemic options. Recent reviews highlight dupilumab as the most extensively studied biologic in children, demonstrating significant improvements in eczema severity scores and quality of life measures with a favorable safety profile (Zemlok et al., 2024). Clinical trials and real-world data confirm its efficacy in children as young as 6 months, with common adverse events including conjunctivitis and injection site reactions, generally mild and manageable.
Traditional systemic immunosuppressants such as cyclosporine and methotrexate have demonstrated efficacy in moderate-to-severe pediatric AD but carry risks of nephrotoxicity, hepatotoxicity, and immunosuppression, necessitating vigilant monitoring (Lugović-Mihić et al., 2024). Pimecrolimus, a topical calcineurin inhibitor, remains a valuable adjunct, especially in infants, with expert consensus supporting its safety and efficacy in this population (Luger et al., 2021).
Emerging systemic therapies, including JAK inhibitors, show promise but require further pediatric-specific safety and efficacy data before routine use (Zemlok et al., 2024). Allergen-specific immunotherapy is not currently a standard systemic treatment for AD but may have adjunctive roles in IgE-mediated allergic comorbidities (Pfaar et al., 2014).
Caveats and uncertainty
Despite advances, high-quality, long-term pediatric data remain limited for many systemic agents. Most clinical trials have relatively short durations and exclude children with significant comorbidities, limiting generalizability. Safety concerns, particularly regarding immunosuppression and growth effects, warrant cautious interpretation of existing data (Zemlok et al., 2024).
Comparative effectiveness studies directly contrasting systemic agents in pediatric AD are scarce, complicating optimal agent selection. The heterogeneity of pediatric AD phenotypes and variable disease courses further challenge treatment standardization (Lugović-Mihić et al., 2024).
Additionally, access and cost considerations may limit biologic use in some settings, and long-term immunogenicity or rare adverse events remain under-characterized. Expert consensus emphasizes individualized treatment plans incorporating shared decision-making and regular reassessment (Luger et al., 2021).
How this may change practice
Clinicians managing pediatric AD should consider dupilumab as a first-line systemic option for moderate-to-severe disease refractory to topical therapies, given its robust evidence base and safety profile. Traditional systemic immunosuppressants remain relevant but require judicious use with appropriate monitoring protocols.
Incorporating multidisciplinary care, including allergy and immunology consultation, may optimize management of complex cases and comorbidities. Awareness of emerging systemic agents and ongoing clinical trials is important for future therapeutic planning.
Patient and family education regarding treatment goals, potential risks, and the importance of adherence and monitoring is essential. Clinicians should remain vigilant for new evidence to guide long-term safety assessments and comparative effectiveness in pediatric populations.